Litigation Details for Aragon Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2022)
✉ Email this page to a colleague
Aragon Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-05-13 |
| Court | District Court, D. Delaware | Date Terminated | 2022-08-09 |
| Cause | Assigned To | Colm Felix Connolly | |
| Jury Demand | Referred To | ||
| Patents | 9,481,663 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Aragon Pharmaceuticals, Inc. v. Lupin Limited
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Aragon Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-05-13 | 1 | Complaint | infringement of United States Patent Nos. 9,481,663 (“the 663 Patent” or the “Patent-In-Suit”). 2. … 9. This is an action for patent infringement arising under the Patent Laws of the United States, … THE PATENT-IN-SUIT 35. On November 1, 2016, the 663 Patent, titled “Crystalline…expiration of the Patent-In-Suit, would constitute infringement of one or more claims of the Patent-In-Suit under…the infringement of the Patent-In-Suit, prior to the expiration of the Patent-In-Suit, or such later date | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
